Table 1.
Clinical Characteristics Among Subgroups According to hs‐TNT Level in the Prospective Cohort (n=75)
| Total | hs‐TNT <5 ng/L | hs‐TNT 5 to 14 ng/L | hs‐TNT >14 ng/L | |
|---|---|---|---|---|
| n=75 | n=29 | n=16 | n=30 | |
| Age, y | 43±14 | 45±13 | 41±12 | 43±15 |
| Female, n (%) | 47 (62.7) | 19 (65.5) | 12 (75) | 16 (53.3) |
| BMI, kg/m² | 25±5 | 24±4 | 25±4 | 25±6 |
| hs‐TNT*, ng/L | 7.7 (4–20.8) | 4 | 7.7 (6.7–8.4)† | 24.2 (19.1–44.1)†, ‡ |
| NT‐proBNP*, pg/mL | 99 (41–224) | 49.5 (28.5–77.5) | 80.5 (33.5–153.5) | 221 (106–910)†, ‡ |
| Cardiovascular, n (%) | ||||
| NYHA class III/IV | 3 (4.0) | 1 (3.4) | 0 (0) | 2 (6.7) |
| CAD | 3 (4.0) | 0 | 0 | 3 (10.0) |
| MI | 0 | 0 | 0 | 0 |
| Bypass | 1 (1.3) | 0 | 0 | 1 (3.3) |
| ICD/pacemaker | 7 (6.7) | 0 | 0 | 5 (16.7)†, ‡ |
| Renal | ||||
| eGFR, mL/min | 83±23 | 97±22 | 80±18† | 70±19† |
| Creatinine, mg/dL | 1.0±0.3 | 0.8±0.2 | 0.9±0.2 | 1.1±0.3† |
| Proteinuria, n (%) | 22 (29.3) | 6 (20.7) | 2 (12.5) | 14 (46.7)†, ‡ |
| Renal insufficiency: 0/I/II/III/IV, % | 64/0/2/6/3 (84.2/0/2.6/7.9/4.0) | 28/0/1/0/0 (96.6/0/3.4/0/0) | 14/0/0/2/0 (87.5/0/0/12.5/0) | 22/0/1/4/3 (71/0/3.2/12.9/10.0) |
| Renal transplantation, n (%) | 3 (4.0) | 0 | 0 | 3 (10.0) |
| Neurological, n (%) | ||||
| Vertigo | 37 (49.3) | 11 (37.9) | 10 (62.5) | 16 (53.3) |
| Tinnitus | 24 (32.0) | 5 (17.2) | 4 (25.0) | 15 (50)† |
| Hearing loss | 11 (14.7) | 1 (3.4) | 3 (18.8) | 7 (23.3) |
| Depression | 7 (9.3) | 2 (6.9) | 2 (12.5) | 3 (10.0) |
| Dysarthria | 6 (8.0) | 2 (6.9) | 1 (6.3) | 3 (10.0) |
| TIA | 6 (8.0) | 3 (10.3) | 1 (6.3) | 2 (6.7) |
| Stroke | 7 (9.3) | 1 (3.4) | 1 (6.3) | 5 (16.7) |
| Gastrointestinal, n (%) | ||||
| Nausea | 7 (9.3) | 3 (10.3) | 1 (6.3) | 3 (10.0) |
| Diarrhea | 24 (32.0) | 5 (17.2) | 5 (31.3) | 14 (46.7) |
| Abdominal pain | 21 (28.0) | 5 (17.2) | 5 (31.3) | 11 (36.7) |
| Acroparesthesia, n (%) | 43 (57.3) | 16 (55.2) | 8 (50) | 19 (63.3) |
| Chronic pain, n (%) | 20 (26.7) | 8 (27.6) | 2 (12.5) | 10 (33.3) |
| Pain crisis, n (%) | 24 (32.0) | 10 (34.5) | 3 (18.8) | 11 (36.7) |
| Medication, n (%) | ||||
| ACE/AT1 | 46 (61.3) | 8 (27.6) | 12 (75)† | 26 (86.7)† |
| ß‐blockers | 10 (13.3) | 3 (10.3) | 2 (12.5) | 5 (16.7) |
| Calcium antagonists | 3 (4.0) | 1 (3.4) | 0 (0) | 2 (6.7) |
| Anticoagulant | 4 (5.3) | 0 | 0 | 4 (13.3) |
| Regular pain medication | 13 (17.3) | 6 (20.7) | 1 (6.3) | 6 (20.0) |
ACE indicates angiotensin‐converting enzyme inhibitor; AT1, angiotensin II type 1 antagonists; BMI, body mass index; CAD, coronary arterial disease; eGFR, estimated glomerular filtration rate; hs‐TNT, high‐sensitivity cardiac troponin T; ICD, implantable cardioverter‐defibrillator; MI, myocardial infarction; NT‐proBNP, N‐terminal of the prohormone brain natriuretic peptide; NYHA, New York Heart Association; TIA, transient ischemic attack.
*Natural logarithm (Ln) transformed.
Bonferroni‐adjusted † P<0.025 vs hs‐TNT <5 ng/L; ‡ P<0.025 vs hs‐TNT 5 to 14 ng/L.